Suven Life Sciences quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	3.6	1.9	+91.0%
EBITDA	−133	−50.7	—
EBITDA margin	−3,715.9%	−2,718.6%	−997.3 pts
Profit before tax	−128	−51.5	—
Net profit	−128	−51.5	—
EPS	−₹4.84	−₹2.36	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	3.6	1.5	2.8	0.9	1.9	1.5	1.6	2.6	1.0	2.4	2.5	3.1	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	7.5	6.8	2.8	3.8	0.6	1.2	1.6	4.0	4.0	4.3	6.1	5.1
	11.1	8.3	5.6	4.7	2.5	2.7	3.2	6.6	5.0	6.7	8.5	8.2
	7.3	5.8	6.3	6.1	6.0	6.1	4.9	5.2	4.7	3.5	5.8	4.4
	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	2.2	1.6	1.3	1.3	1.4	1.3	1.5	1.5	1.5	1.5	1.6	1.7
	129	46.3	99.9	74.6	46.6	39.2	35.9	49.6	26.9	29.2	42.8	22.1
	139	53.9	108	82.0	54.0	46.6	42.4	56.3	33.1	34.2	50.3	28.3
	−133	−50.6	−103	−79.8	−50.7	−43.8	−39.2	−52.2	−30.5	−30.3	−46.2	−23.5
	−135	−52.2	−105	−81.1	−52.1	−45.2	−40.7	−53.7	−32.0	−31.8	−47.8	−25.2
Profit
	−128	−45.6	−102	−77.3	−51.5	−43.9	−39.1	−49.6	−28.0	−27.5	−41.8	−20.1
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.5
	−128	−45.6	−102	−77.3	−51.5	−43.9	−39.1	−49.6	−28.0	−27.5	−41.8	−12.7
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−1.0	0.0	0.0
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−1.0	0.0	0.0
	−128	−45.6	−102	−77.3	−51.5	−43.9	−39.1	−49.6	−28.0	−26.5	−41.8	−12.7
	−128	−45.6	−102	−77.3	−51.5	−43.9	−39.1	−49.6	−28.0	−26.5	−41.8	−12.7
	−0.0	−0.5	−0.8	0.1	−0.1	−0.6	−0.0	−0.0	−0.0	−0.2	0.0	0.0
	−128	−46.1	−103	−77.2	−51.6	−44.5	−39.1	−49.6	−28.0	−26.7	−41.7	−12.6
	—	—	—	−77.3	−51.5	—	−39.1	−49.6	−28.0	—	−41.8	−12.7
Per share
	−₹4.84	−₹2.02	−₹4.55	−₹3.48	−₹2.36	−₹2.02	−₹1.79	−₹2.27	−₹1.29	−₹1.22	−₹1.92	−₹0.58
	−₹4.84	−₹2.02	−₹4.55	−₹3.48	−₹2.36	−₹2.02	−₹1.79	−₹2.27	−₹1.29	−₹1.22	−₹1.92	−₹0.58
Other comprehensive income — detail
	−0.0	−0.5	−0.8	0.1	−0.1	−0.6	—	—	—	—	—	—
	−0.0	−0.2	0.0	−0.0	—	−0.6	−0.0	−0.0	−0.0	—	0.0	0.0
	0.0	0.0	0.0	0.0	0.0	0.0	—	—	—	—	—	—
	—	—	—	—	—	—	0.0	0.0	0.0	0.2	0.0	0.0
	—	−0.2	−0.8	0.1	—	—	—	—	—	—	—	—
	0.0	0.0	0.0	0.0	0.0	0.0	—	—	—	—	—	—
	—	—	—	−77.3	−51.5	—	−39.1	−49.6	−28.0	—	−41.8	−12.7
Per share — as-filed variants
	−₹4.84	−₹2.02	−₹4.55	−₹3.48	−₹2.36	−₹2.02	−₹1.79	−₹2.27	−₹1.29	−₹1.22	−₹1.92	−₹0.58
	−₹4.84	−₹2.02	−₹4.55	−₹3.48	−₹2.36	−₹2.02	−₹1.79	−₹2.27	−₹1.29	−₹1.22	−₹1.92	−₹0.58
Adjusted (ex-exceptional items) — derived
	−128	−45.6	−102	−77.3	−51.5	−43.9	−39.1	−49.6	−28.0	−27.5	−41.8	−20.1
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.5
	−128	−45.6	−102	−77.3	−51.5	−43.9	−39.1	−49.6	−28.0	−26.5	−41.8	−20.1
	−₹4.84	−₹2.02	−₹4.55	−₹3.48	−₹2.36	−₹2.02	−₹1.79	−₹2.27	−₹1.29	−₹1.22	−₹1.92	−₹0.92

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUVEN₹264.20

Suven Life Sciences Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersVIMTALABS TAKEMcap ₹6,967 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	3.1	2.5	2.4	1.0	2.6	1.6	1.5	1.9	0.9	2.8	1.5	3.6
Other Income	5.1	6.1	4.3	4.0	4.0	1.6	1.2	0.6	3.8	2.8	6.8	7.5
Total Income	8.2	8.5	6.7	5.0	6.6	3.2	2.7	2.5	4.7	5.6	8.3	11.1
Expenses
+ Employee Benefit Expense	4.4	5.8	3.5	4.7	5.2	4.9	6.1	6.0	6.1	6.3	5.8	7.3
+ Finance Costs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.5
+ Depreciation & Amortisation	1.7	1.6	1.5	1.5	1.5	1.5	1.3	1.4	1.3	1.3	1.6	2.2
+ Other Expenses	22.1	42.8	29.2	26.9	49.6	35.9	39.2	46.6	74.6	99.9	46.3	128.8
Total Expenses	28.3	50.3	34.2	33.1	56.3	42.4	46.6	54.0	82.0	107.5	53.9	138.7
EBITDA	-23.5	-46.2	-30.3	-30.5	-52.2	-39.2	-43.8	-50.7	-79.8	-103.4	-50.6	-132.5
EBIT	-25.2	-47.8	-31.8	-32.0	-53.7	-40.7	-45.2	-52.1	-81.1	-104.7	-52.2	-134.7
Profit
PBT before Exceptional Items	-20.1	-41.8	-27.5	-28.0	-49.6	-39.1	-43.9	-51.5	-77.3	-101.9	-45.6	-127.6
+ Exceptional Items	7.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Pretax Income	-12.7	-41.8	-27.5	-28.0	-49.6	-39.1	-43.9	-51.5	-77.3	-101.9	-45.6	-127.6
+ Current Tax	0.0	0.0	-1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Expense	0.0	0.0	-1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Income	-12.7	-41.8	-26.5	-28.0	-49.6	-39.1	-43.9	-51.5	-77.3	-101.9	-45.6	-127.6
+ Net Income — Continuing Ops	-12.7	-41.8	-26.5	-28.0	-49.6	-39.1	-43.9	-51.5	-77.3	-101.9	-45.6	-127.6
+ Other Comprehensive Income	0.0	0.0	-0.2	-0.0	-0.0	-0.0	-0.6	-0.1	0.1	-0.8	-0.5	-0.0
Total Comprehensive Income	-12.6	-41.7	-26.7	-28.0	-49.6	-39.1	-44.5	-51.6	-77.2	-102.7	-46.1	-127.6
Net Income to Common	-12.7	-41.8	—	-28.0	-49.6	-39.1	—	-51.5	-77.3	—	—	—
Per Share
Basic EPS	-0.58	-1.92	-1.22	-1.29	-2.27	-1.79	-2.02	-2.36	-3.48	-4.55	-2.02	-4.84
Diluted EPS	-0.58	-1.92	-1.22	-1.29	-2.27	-1.79	-2.02	-2.36	-3.48	-4.55	-2.02	-4.84
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-0.6	-0.1	0.1	-0.8	-0.5	-0.0
+ Items NOT to be Reclassified to P&L	0.0	0.0	—	-0.0	-0.0	-0.0	-0.6	—	-0.0	0.0	-0.2	-0.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.0	0.0	0.0	0.0	0.0	0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.0	0.0	0.2	0.0	0.0	0.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	—	—	—	—	—	—	—	0.1	-0.8	-0.2	—
+ Tax on Items to be Reclassified	—	—	—	—	—	—	0.0	0.0	0.0	0.0	0.0	0.0
Comprehensive Income — Owners of Parent	-12.7	-41.8	—	-28.0	-49.6	-39.1	—	-51.5	-77.3	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	-0.58	-1.92	-1.22	-1.29	-2.27	-1.79	-2.02	-2.36	-3.48	-4.55	-2.02	-4.84
Diluted EPS — Continuing Operations	-0.58	-1.92	-1.22	-1.29	-2.27	-1.79	-2.02	-2.36	-3.48	-4.55	-2.02	-4.84
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-20.1	-41.8	-27.5	-28.0	-49.6	-39.1	-43.9	-51.5	-77.3	-101.9	-45.6	-127.6
− Exceptional Items (reconciliation)	7.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Income Adj (tax-effected)	-20.1	-41.8	-26.5	-28.0	-49.6	-39.1	-43.9	-51.5	-77.3	-101.9	-45.6	-127.6
EPS Adj	-0.92	-1.92	-1.22	-1.29	-2.27	-1.79	-2.02	-2.36	-3.48	-4.55	-2.02	-4.84
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	21.8	21.8	21.8	21.8	21.8	21.8	21.8	21.8	22.7	22.7	26.4	26.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Suven Life Sciences Q2 FY27 results date

Suven Life Sciences (NSE: SUVEN) will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, according to the board-meeting notice it filed on 29 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net loss was ₹128 crore, wider than the loss of ₹51.5 crore in Q1 FY26 and wider than the loss of ₹45.6 crore in Q4 FY26. Revenue from operations was ₹3.6 crore, up 91.0% year on year and up 134.6% from the previous quarter.

Board-meeting notice filed: 29 October 2026
Q2 FY26 results (a year earlier): 11 November 2025
Q1 FY27 results (the latest): 6 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 5 November 2026Thursday · notice filed 29 Oct
Q1 FY27 net loss: −₹128 Crloss ₹51.5 Cr in Q1 FY26loss ₹45.6 Cr in Q4 FY26
Q1 FY27 revenue: ₹3.6 Cr+91.0% vs Q1 FY26+134.6% vs Q4 FY26
Q2 FY26 net loss (a year earlier): −₹77.3 CrRevenue ₹92 lakh
Q1 FY27 EPS (basic): −₹4.84

Questions

When will Suven Life Sciences announce its Q2 FY27 results?

On 5 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 29 October 2026). Last year it reported Q2 FY26 on 11 November 2025.

What will Suven Life Sciences' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net loss was ₹77.3 crore and revenue from operations ₹92 lakh. The latest quarter, Q1 FY27, had a net loss of ₹128 crore and revenue of ₹3.6 crore.

What was Suven Life Sciences' net profit in FY26?

Consolidated net profit was a loss of ₹276 crore in FY26 (April 2025–March 2026), wider than the loss of ₹161 crore in FY25. It was a loss of ₹105 crore in FY24 and a loss of ₹118 crore in FY23.

What were Suven Life Sciences' Q1 FY27 results?

Consolidated net loss was ₹128 crore, wider than the loss of ₹51.5 crore in Q1 FY26 and wider than the loss of ₹45.6 crore in Q4 FY26. Revenue from operations was ₹3.6 crore, up 91.0% year on year and up 134.6% from the previous quarter.

How has Suven Life Sciences' profit changed over the last four quarters?

Net profit by quarter: a loss of ₹77.3 crore in Q2 FY26, a loss of ₹102 crore in Q3 FY26, a loss of ₹45.6 crore in Q4 FY26 and a loss of ₹128 crore in Q1 FY27. That is a combined loss of ₹352 crore over the four quarters. Revenue from operations: ₹92 lakh, ₹2.8 crore, ₹1.5 crore and ₹3.6 crore.

What was Suven Life Sciences' revenue in FY26?

Revenue from operations was ₹7.1 crore in FY26 (April 2025–March 2026), up 6.9% from ₹6.7 crore in FY25. It was ₹11.7 crore in FY24 and ₹13.5 crore in FY23: down 47.5% over three years, an average fall of 19.3% a year.

Where do these Suven Life Sciences figures come from?

From Suven Life Sciences' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.